<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642820</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-0364</org_study_id>
    <nct_id>NCT04642820</nct_id>
  </id_info>
  <brief_title>Drugs Brain and Behavior (DDP)</brief_title>
  <acronym>DDP</acronym>
  <official_title>Drugs Brain and Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project, we will examine individual differences in the effects of a stimulant drug,&#xD;
      methamphetamine (MA), on mesolimbic reward function using fMRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SUbjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Sub-scales of Drug Effects Questionnaire (DEQ).</measure>
    <time_frame>Time Frame: Day 1(baseline), 3</time_frame>
    <description>Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot;. All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Stimulant Use</condition>
  <arm_group>
    <arm_group_label>Placebo Then Methamphetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MethamphetamineThen Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methamphetamine</intervention_name>
    <description>Participants will be given 20 mg of Methamphetamine.</description>
    <arm_group_label>MethamphetamineThen Placebo</arm_group_label>
    <arm_group_label>Placebo Then Methamphetamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo oral tablet</intervention_name>
    <description>Participants will be given a placebo capsule that will only contain lactose.</description>
    <arm_group_label>MethamphetamineThen Placebo</arm_group_label>
    <arm_group_label>Placebo Then Methamphetamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 19 and 26&#xD;
&#xD;
          -  Right Handed&#xD;
&#xD;
          -  Less than 4 alcohol or caffeinated beverages a day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High blood pressure&#xD;
&#xD;
          -  Any medical condition requiring regular medication&#xD;
&#xD;
          -  Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis&#xD;
&#xD;
          -  Individuals with a history of dependence on stimulant drugs&#xD;
&#xD;
          -  Women who are pregnant or trying to become pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet de Wit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Bona</last_name>
    <phone>773-702-3560</phone>
    <email>dewitlab@yoda.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bona</last_name>
      <email>dewitlab@yoda.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

